ГоловнаArchive of numbers2016Volume 24, issue 1 (86)Peculiarities of a comprehensive treatment of paranoid schizophrenia, comorbid with bone tuberculosis, in aspects of their pharmaco therapy and psychosocial rehabilitation
Title of the article Peculiarities of a comprehensive treatment of paranoid schizophrenia, comorbid with bone tuberculosis, in aspects of their pharmaco therapy and psychosocial rehabilitation
Authors Shyrokov Oleksandr
In the section DIAGNOSTICS AND THERAPY OF MENTAL AND NARCOLOGICAL DISORDERS
Year 2016 Issue Volume 24, issue 1 (86) Pages 97-100
Type of article Scientific article Index UDK 616.89-02-085::[616.71/002.52] Index BBK -
Abstract Comorbidity schizophrenia and tuberculosis has due-complication effect: the presence of a mental disorder (schizophrenia), worsens the prognosis for recovery from active tuberculosis, but also the presence of the latter worsens the prognosis of schizophrenia. Existing studies show that patients who have comorbid schizophrenia and tuberculosis require longer treatment in hospital, the worst weather on the results of therapy as schizophrenia (usually remission is achieved at a later date) and tuberculosis (higher risk extrapulmonal and severe forms, more long-term treatment). Obviously, these patients require treatment modification. It should be borne immunomodulatory and antibacterial properties of certain psychotropic and neuroleptic effects of anti-TB drugs. In addition, the quality of life of patients with schizophrenia and comorbid TB requires additional psychosocial interventions.
Key words paranoid schizophrenia, bone tuberculosis, comorbid disadaptation, complex treatment
Access to full text version of the article pdf download
Bibliography 1. Борзенко А. С. Оценка эффективности стационарного этапа лечения при оказании противотуберкулезной помощи психически больным, страдающим туберкулезом легких / А. С. Борзенко, Е. Ю. Зубова, Ю. А. Яицкий // Проблемы туберкулеза и болезней легких. — 2007. — № 6. — С 37—40. 2. Фещенко Ю. І. Фтизіоепідеміологія / Ю. І. Фещенко, В. М. Ме- ль ник. — К.: Здоров’я, 2004. — 624 с. 3. Амлаев К. Р. Туберкулез легких у психических больных: эпидемиологические и клинические аспекты / К. Р. Амлаев, О. Д. Баронова // Профилактическая медицина. — 2011. — № 2. — С. 45—48. 4. Зубова Е. Ю. Туберкулез легких в психиатрических стацио- нарах / Е. Ю. Зубова // Вестник ТГУ. — 2012. — Т. 17, вып. 1. — С. 256—262. 5. A new rating scale for negative symptoms: The Motor-Affective- Social Scale // Psychiatry Research. — Vol. 160. — Issue 3. — 30 September 2008. — P. 346—355. 6. WHO Psychiatric Disability Assessment Schedule (WHO/DAS) with a Guide to its Use. — Geneva : WHO, 1988. — 96 р. 7. Критерий качества жизни в психиатрической практике / Н. А. Марута, Т. В. Панько, И. А. Явдак [и др.]. — Х.: РИФ Арсис, ЛТД, 2004. — 239 с. 8. Путятин Г. Г. Клинико-динамические и социально-психоло- гические аспекты проблемы госпитализма у больных шизофре- нией / Г. Г. Путятин // В кн. : Абрамов В. А. Психосоциальная ре- абилитация больных шизофренией / В. А. Абрамов, И. В. Жигули на, Т. Л. Ряполова. — Донецк : Каштан, 2009. — С. 65—110. 9. Psychotropic effects of antimicrobials and immune modulation by psychotropics: implications for neuroimmune disorders / D. Obregon, E. C. Parker-Athill, J. Tan, T. Murphy // Neuropsychiatry. — 2012. — Vol. 2(4). — P. 331—343. 10. Joint Formulary Committee. British National Formulary. — London: BMJ Group and Pharmaceutical Press, 2014. — 1144 p. 11. Brunton L. Goodman and Gilman's the Pharmacological Basis of Therapeutics / L. Brunton, B. Chabner, B. Knollman. — 12th ed. — N. Y. : McGraw-Hill Education, 2011. — 1808 p. 12. An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid / T. M. Polasek, D. J. Elliot, A. A. Somogyi [et al.] // British Journal of Clinical Pharmacology. — 2006. — Vol. 61(5). — P. 570—584. 13. Kucharz E. J. Studies on immunomodulatory properties of isoniazid. I. Effect of isoniazid on mitogen- and anti-CD3 antibody- induced proliferation of human peripheral blood mononuclear cells and T cells / E. J. Kucharz, S. J. Sierakowski // Journal of Hygiene, Epidemiology, Microbiology, and Immunology. — 1990. — Vol. 34(1). — P. 99—105. 14. Kucharz E. J. Studies on immunomodulatory properties of isoniazid. III. Effect of isoniazid on proliferation of interleukindependent and interleukin-independent cell line / E. J. Kucharz, S. J. Sierakowski // Ibid. — 1990. — Vol. 34(3). — P. 305—308. 15. Bleakley S. Identifying and reducing the risk of antipsychotic drug interactions / S. Bleakley // Progress in Neurology and Psychiatry. — 2012. — Vol. 16(2). — P. 20—24. 16. Pai M.-S. Rifampin-zotepine interaction reduces effectiveness of antipsychotic drugs in a stable schizophrenia patient / M.-S. Pai, S.-H. Yang, I.-S. Shiah // Psychiatry and Clinical Neurosciences. — 2012. — Vol. 66(6). — P. 538. 17. Therapeutic drug monitoring in the treatment of tuberculosis patients / C. Magic-Escurra, J. van den Boogaard, D. Ijdema [et al.] // Pulmonary Pharmacology and Therapeutics. — 2012. — Vol. 25(1). — P. 83—86. 18. Visual evoked responses in tuberculous children on enthambutol therapy / [V. Seth, P. K. Khosla, O. P. Semwal, V. D`Monty] // Indian Academy of Pediatrics. — 1991. — Vol. 28(7). — P. 713—717. 19. Holdiness M. R. Neurological manifestations and toxicities of the antituberculosis drugs: a review / M. R. Holdiness // Medical Toxicology and Adverse Drug Experience. — 1987. — Vol. 2(1). — P. 33—51. 20. Kass J. S. Nervous System Effects of Antituberculosis Therapy / J. S. Kass, W. X. Shandera // CNS Drugs. — 2010. — Vol. 24(8). — P. 655—667. 21. In vivo immunomodulatory effects of clozapine in schizophrenia / M. Maes, E. Bosmans, G. Kenis [et al.] // Schizophrenia Research. — 1997. — Vol. 26(2—3). — P. 221—225. 22. Geiger H. Largactil in the treatment of tuberculosis / H. Geiger, B. A. Finkelstein // Schweizerische medizinische Wochenschrift. — 1954. — Vol. 84. — P. 1063—1064. 23. Fisher R. A. Clinical experience with ataractic therapy in tuberculous psychiatric patients / R. A. Fisher, E. Teller // Diseases of the Chest. — 1959. — Vol. 35. — P. 134—139. 24. Psychopharmacology Frontiers / N. S. Kline (ed.). — Boston : Little Brown, 1959. — 533 p. 25. Kivimiagi E. A. Treatment with aminazin of patients with schizophrenia suffering from pulmonary tuberculosis / E. A. Kivimiagi, E. A. Iudovich // Zhurnal nevropatologii i psikhiatrii imeni S. S. Korsakova. — 1963. — Vol. 61. — P. 247—250. 26. Mosin N. I. Aminazin therapy of schizophrenie patients with pulmonary tuberculosis / N. I. Mosin // Zhurnal nevropatologii i psikhiatrii imeni S. S. Korsakova. — 1961. — Vol. 64. — P. 609—613. 27. Bettencourt M. V. Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis / M. V. Bettencourt, S. Bosne-David, L. Amaral // International Journal of Antimicrobial Agents. — 2000. — Vol. 16(1). — P. 69—71. 28. Inhibition of the respiratory of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial freshly diagnosed tuberculosis / [L. Amaral, J. E. Kristiansen, L. S. Abebe, W. Millett] // Journal of Antimicrobial Chemotherapy. — 1996. — Vol. 38. — P. 1049—1053. 29. Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting futher studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy / [L. Amaral, J. E. Kristiansen, M. Viveiros, J. Atouguia] // Ibid. — 2001. — Vol. 47(5). — P. 505—511.